Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment

Pasi A. Jänne, Melissa L. Johnson, Kyriakos P. Papadopoulos et al.|Molecular Cancer Therapeutics|2023

Cited by 60